Article Details
Retrieved on: 2018-04-29 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>San Diego-based Synthorx has brought in $63 million in Series C financing to advance its efforts to produce semi-synthetic protein therapies for cancer and immune conditions. The funding round was led by OrbiMed with others such as Medicxi, Osage University Partners, <b>Avalon Ventures</b>, RA Capital ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here